Antibody

α-synuclein (LB509)

Tools

Back to the Top

Clonality: monoclonal
Host: Mouse
Isotype: IgG1,κ
Source: Zymed/ Invitrogen
Cat# 18-0215
References:
Paleologou, 2010
Lo Bianco, 2008
Ihara, 2007
Josephs, 2007
Tsigelny, 2007
Sherer, 2002
Formulation: IHC concentrate; available diluted ready-to-use cat # 08-1215
Reactivity:
Reacts in: Human

Immunogen/Epitope

immunogen = Lewy bodies purified from patients suffering from DLB

Specificity

α-synuclein; not β- or γ-synuclein

Comments / Questions

No Available Comments

Make a comment or submit a question

To make a comment you must login or register.

References

Paper Citations

  1. Paleologou KE, Oueslati A, Shakked G, Rospigliosi CC, Kim HY, Lamberto GR, Fernandez CO, Schmid A, Chegini F, Gai WP, Chiappe D, Moniatte M, Schneider BL, Aebischer P, Eliezer D, Zweckstetter M, Masliah E, Lashuel HA. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci. 2010 Mar 3;30(9):3184-98. PubMed.
  2. Lo Bianco C, Shorter J, Régulier E, Lashuel H, Iwatsubo T, Lindquist S, Aebischer P. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest. 2008 Sep;118(9):3087-97. PubMed.
  3. Ihara M, Yamasaki N, Hagiwara A, Tanigaki A, Kitano A, Hikawa R, Tomimoto H, Noda M, Takanashi M, Mori H, Hattori N, Miyakawa T, Kinoshita M. Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron. 2007 Feb 15;53(4):519-33. PubMed.
  4. Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, Knopman DS, Boeve BF, Parisi JE, Petersen RC, Dickson DW, Jack CR. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol. 2008 Feb;63(2):204-12. PubMed.
  5. Tsigelny IF, Bar-On P, Sharikov Y, Crews L, Hashimoto M, Miller MA, Keller SH, Platoshyn O, Yuan JX, Masliah E. Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J. 2007 Apr;274(7):1862-77. PubMed.
  6. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci. 2002 Aug 15;22(16):7006-15. PubMed.

Further Reading